With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
Executive Summary
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
You may also be interested in...
Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules
CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.
Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells
Obsidian CEO Michael Gilman described the company's technology – which allows CAR-T cells and other therapies to be activated by available small molecule drugs – as being able to modulate the effective yet toxic therapies by dialing down, turning up or shutting off the treatments as needed.
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.